By Fineline Cube 
Sanofi (NASDAQ: SNY) today reported its third‑quarter 2025 financial performance, posting a 7 % year‑on‑year increase in global revenues in constant‑currency terms to €12.43 billion ($14.43 billion). Over the first nine months of the year, sales climbed 8.7 % YOY to €32.32 billion ($37.5 billion).
Financial Highlights
| Metric | Q3 2025 | YoY % | 1‑9 M 2025 | YoY % |
|---|---|---|---|---|
| Global Revenue | €12.43 bn | +7.0 % | – | – |
| Total Sales | €12.43 bn | +7.0 % | €32.32 bn | +8.7 % |
| Pharma Sales | €? bn | +? % | €? bn | +? % |
| Vaccine Sales | €3.80 bn | –7.8 % | – | – |
| Other Medicines | €3.80 bn | –3.8 % | – | – |
Key drivers: 40.8 % sales growth in newly launched medicines and vaccines; 26.2 % expansion for allergy drug Dupixent (dupilumab), which surpassed €4 bn in quarterly global sales for the first time.
Dupixent & Pharma Momentum
- Dupixent sales reached €4.20 bn ($4.90 bn), breaking both the €4 bn quarterly global sales threshold and the €3 bn U.S. mark.
- Pharma launches grew 57.1 % to €1.00 bn ($1.20 bn), driven by hemophilia drug ALTUVIIIO (rFVIII) and RSV vaccine Beyfortus.
- The vaccine business declined 7.8 % to €3.80 bn, offset by Dupixent’s robust performance.
Geographic Performance
| Region | Q3 2025 Sales (€ mln) | YoY % | 1‑9 M Sales (€ mln) | YoY % |
|---|---|---|---|---|
| United States | 6,838 | +11.1 % | 16,373 | +14.1 % |
| Europe | 2,589 | +2.8 % | 6,733 | +2.2 % |
| Rest of World | 3,007 | +1.9 % | 9,217 | +4.9 % |
| China | 689 | +2.7 % | 2,077 | +0.9 % |
China’s modest 2.7 % growth occurred amid a “slightly declining market” influenced by the renewed national reimbursement drug list and volume‑based procurement.
Regulatory Milestones
- China: FDA‑like approval of CD3‑targeted antibody Tzield (teplizumab) to delay progression of Type 1 diabetes.
- U.S.: Global approval of Bruton’s tyrosine kinase inhibitor Wayrilz (rilzabrutinib) for immune thrombocytopenia; a major launch with potential across rare diseases.
- Q3 2025: Eight new approval filings; six additional regulatory decisions expected in Q4 2025.
Outlook
Sanofi’s Q3 results underscore the strength of its newly launched portfolio and the flagship Dupixent. The company remains focused on expanding its rare‑disease pipeline and capturing growth in high‑margin specialty markets while navigating competitive vaccine dynamics.-Fineline Info & Tech